US Edition
News from Pharmacy Times
We’ve assigned a rating of Unknown factuality to Pharmacy Times. You can read more about how we’ve determined Pharmacy Times’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmacy Times News
FDA · United States(MedPage Today) -- The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial depletion syndrome, the agency announced on Monday.
A pair of pyrimidine nucleosides, the doxecitine...See the Story
Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug
60% Center coverage: 25 sources
Drug Prices · United StatesKey TakeawaysMFN tariffs could reshape drug pricing and access, with potential long-term implications depending on legislative changes and voluntary agreements.DTC channels disrupt traditional pharmacy operations, raising compliance concerns and altering the dynamics of drug pricing and patient access.The 340B program's pricing dynamics are linked to MFN, affecting hospital revenues and potentially leading to service reevaluations.Policy [...]See the Story
